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G protein bg subunits inhibit TRPM3 ion
channels in sensory neurons
Talisia Quallo*, Omar Alkhatib, Clive Gentry, David A Andersson, Stuart Bevan*
Wolfson Centre for Age-Related Diseases, King’s College London, London, United
Kingdom
Abstract Transient receptor potential (TRP) ion channels in peripheral sensory neurons are
functionally regulated by hydrolysis of the phosphoinositide PI(4,5)P2 and changes in the level of
protein kinase mediated phosphorylation following activation of various G protein coupled
receptors. We now show that the activity of TRPM3 expressed in mouse dorsal root ganglion (DRG)
neurons is inhibited by agonists of the Gi-coupled m opioid, GABA-B and NPY receptors. These
agonist effects are mediated by direct inhibition of TRPM3 by Gbg subunits, rather than by a
canonical cAMP mediated mechanism. The activity of TRPM3 in DRG neurons is also negatively
modulated by tonic, constitutive GPCR activity as TRPM3 responses can be potentiated by GPCR
inverse agonists. GPCR regulation of TRPM3 is also seen in vivo where Gi/o GPCRs agonists
inhibited and inverse agonists potentiated TRPM3 mediated nociceptive behavioural responses.
DOI: 10.7554/eLife.26138.001
Introduction
Proteins encoded by the TRPM3 gene form non-selective cation channels which are widely
expressed in mammalian tissues. The discovery that TRPM3 can be activated by the endogenous
neurosteroid pregnenolone sulphate (PS), has facilitated the study of this widely-expressed TRP
channel and PS has been utilised as a pharmacological tool for channel characterisation and as a
probe for TRPM3 expression (Wagner et al., 2008). TRPM3 is expressed in peripheral sensory neu-
rons where it acts as a heat sensor (Vriens et al., 2011). Activation of TRPM3 channels in vivo has
been shown to evoke nociceptive behaviours and mice without functional TRPM3 channels exhibit
altered temperature preferences, compromised behavioural responses to noxious heat and fail to
develop heat hyperalgesia associated with inflammation (Vriens et al., 2011).
There have been relatively few studies of the mechanisms which regulate or sensitise TRPM3.
Many TRP channels are regulated by signalling pathways associated with activation of G-protein cou-
pled receptors (GPCRs). For example, activation of both Gas and Gaq- coupled receptors can sensi-
tise the heat sensitive nociceptor TRPV1 through protein kinase-dependent mechanisms
(Bevan et al., 2014). Like other TRP channels, TRPM3 can be regulated by phosphoinositol 4,5-
bisphosphate (PI(4,5)P2) and other phosphoinositides as loss or hydrolysis of PI(4,5)P2 leads to a
reduction in TRPM3 activity that can be restored by application of exogenous PI(4,5)
P2 (Badheka et al., 2015; To´th et al., 2015). These findings suggest that TRPM3 activity can be reg-
ulated downstream of activation of Gq coupled GPCRs. A human TRPM3 variant with a short car-
boxyl terminus was found to be insensitive to stimulation of Gq-coupled muscarinic receptors or
histamine H1 receptors (Grimm et al., 2003). However, another human splice variant, TRPM3a, was
shown to be activated by muscarinic receptor stimulation (Lee et al., 2003), suggesting that individ-
ual genetic variants can be differentially regulated. Units of the G protein itself can directly interact
with channel structures to modulate ion channel activity. Indeed activation of Gaq-linked receptors
inhibits TRPM8 via a direct action of the Gaq subunit with the TRPM8 channel (Zhang et al., 2012)
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and TRPM1 is inhibited by interactions with either Ga or Gbg subunits (Shen et al., 2012; Xu et al.,
2016).
In this study we have examined the effects of GPCR activation on the function of endogenously
expressed TRPM3 channels in isolated DRG neurons from mice and investigated if activation of Gi/o
coupled GPCRs can modulate TRPM3 mediated nociceptive responses in vivo. For these experi-
ments we have studied three different receptors (opioid, GABAB and neuropeptide Y) which are
known to modulate sensory neuron activity (Levine and Taiwo, 1989; Schuler et al., 2001;
Smith et al., 2007). We have also examined the underlying mechanism in CHO and HEK293 cells
exogenously expressing TRPM3. Our results demonstrate that activation of these GPCRs inhibits
TRPM3 activity in DRG neurons by a Gbg mediated mechanism and inhibits PS-evoked nociceptive
responses in mice.
Results
Morphine, Baclofen and PYY inhibit TRPM3 mediated PS-induced Ca2+
responses
Opioids remain one of the best known and most effective treatments for pain, and Gi/o coupled
GPCRs for opioid ligands are expressed on sensory neurons where receptor activation inhibits volt-
age-gated calcium channels (VGCCs) (Stein et al., 2003). Therefore, to determine if activation of Gi/
o GPCRs can modulate natively expressed TRPM3 channels, we first examined the effects of the pro-
totypical opioid receptor agonist, morphine.
eLife digest TRPM3 belongs to a family of channel proteins that allow sodium and calcium ions
to enter cells by forming pores in cell membranes. TRPM3 is found on the cell membranes of nerve
cells; when ions flow into the nerves through the TRPM3 pores it triggers an electrical impulse.
TRPM3 is responsible for helping us to detect heat, and mice without this protein find it difficult to
sense painfully hot temperatures. Mice lacking TRPM3 also respond to other kinds of pain
differently. Normally, a mouse with an injured paw becomes more sensitive to warm and hot
temperatures, but this does not happen in mice that do not have TRPM3.
When activated, other proteins called G-protein coupled receptors (or GPCRs for short) can make
some members of this family of channel proteins more or less likely to open their pore. This in turn
increases or decreases the flow of ions through the pore, respectively. Yet it was not clear if GPCRs
also affect TRPM3 channels on the membranes of nerve cells.
Quallo et al. have now discovered that “switching on” different GPCR proteins in sensory nerve
cells from mice greatly reduces the flow of calcium ions though TRPM3 channels. The experiments
made use of two pain-killing drugs, namely morphine and baclofen, and a molecule called
neuropeptide Y to activate different GPCRs.
GPCRs interact with a group of small proteins called G-proteins that, when activated by the
receptor, split into two subunits, known as the a subunit and the bg subunit. Once detached these
subunits are free to act as messengers and interact with other proteins in the cell membrane. Quallo
et al. found that TRPM3 is one of a small group of proteins that interact with the bg subunits of the
G-protein, which can explain how “switching on” GPCRs reduces the activity of TRPM3. Two
independent studies by Dembla, Behrendt et al. and Badheka, Yudin et al. also report similar
findings.
There is currently a need to find more effective treatments for people suffering from long-term
pain conditions and it has become clear that TRPM3 channels are involved in sensing both pain and
temperature. These new findings show that drugs already used in the treatment of pain can
dramatically change how TRPM3 works. These results might help scientists to find drugs that work in
a similar way to dial down the activity of TRPM3 and to combat pain. Though first it will be
important to confirm these new findings in human nerve cells.
DOI: 10.7554/eLife.26138.002
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We used two consecutive applications of a submaximal concentration of pregnenolone sulphate
(PS, 20 mM,) to investigate the effect of morphine on TRPM3-mediated [Ca2+]i-responses in isolated
DRG neurons. This concentration of PS typically activates about 30% of cells in DRG cultures. The
first application of PS was used to identify TRPM3 expressing neurons and the second to assess the
effects of pharmacological treatments. We refer to the response amplitude of the second PS chal-
lenge as R (relative % response). In control experiments, the second PS challenge evoked [Ca2+]i-
responses (R) that were 63 ± 2% of the first PS response amplitude (Figure 1a). Treatment with mor-
phine (10 mM) for 2 min before and during the second PS challenge significantly reduced R to 12 ±
1% (p<0.001, Figure 1b,c). In the majority of PS-responsive neurons (55%, n = 115/209), application
of morphine completely abolished PS-evoked [Ca2+]i responses (R < 5%).
To confirm that the inhibitory effect of morphine is receptor mediated and not a direct effect of
morphine on TRPM3, we examined the effect of morphine in the presence of the opioid receptor
antagonist, naloxone. Naloxone (1 mM) inhibited the effect of morphine (10 mM) completely, since
the relative amplitude (R) produced by the second PS challenge in the presence of morphine plus
naloxone was 73 ± 3% (p>0.05, Figure 1d), very similar to untreated control neurons (R = 64 ± 3%).
Thus morphine inhibits TRPM3 by activating an opioid receptor present on DRG neurons.
The involvement of Gi/o proteins was investigated using pertussis toxin (PTX), which inhibits the
coupling of Gi/o proteins to their cognate GPCRs by catalysing ADP-ribosylation of the Gai/o subu-
nits. Incubation with PTX (200 ng/ml, for ~2 ½  18 hr) significantly reduced the inhibitory effect of
morphine in a large proportion of the neurons (morphine: R = 16 ± 2%; morphine +PTX: R = 46 ±
2%, p<0.001, Figure 1d). These findings indicate that activation of a sensory-neuron expressed opi-
oid receptor and subsequent Gai/o protein signalling is able to modulate the activity of TRPM3 chan-
nels. Opioid receptors, like many other types of GPCRs, may possess constitutive, agonist
independent activity (Rosenbaum et al., 2009). We tested whether such tonic receptor activity mod-
ulates the activity of endogenously expressed TRPM3 in DRG neurons, using two consecutive chal-
lenges of a low concentration of PS (5 mM) that evoked [Ca2+]i-responses in only a small percentage
of neurons. In experiments where cells were exposed to naloxone during the second PS challenge
the number of responding neurons increased significantly (p<0.001, Fisher’s) from 3.6% (n = 36/999)
to 9% (90/999, Figure 1e). In contrast, the number of PS responders fell from 3.5% (n = 40/1153) to
1.8% (n = 21/1153) in control experiments. These findings indicate that constitutive activity of opioid
receptors exerts a tonic inhibition of TRPM3 in DRG neurons.
We used patch-clamp recordings to confirm that the observed opioid receptor mediated inhibi-
tion of PS-evoked [Ca2+]i-responses is associated with a corresponding inhibition of TRPM3 currents
in DRG neurons. TRPM3 currents have a marked outward rectification (Wagner et al., 2008) and we
therefore studied neurons at a holding potential of +40 mV. Application of PS (50 mM) rapidly
evoked membrane currents in a subset of isolated DRG neurons (Figure 1f). Subsequent introduc-
tion of morphine (10 mM) in the continued presence of PS produced a rapid, near-complete and
reversible inhibition of the PS-evoked current. We next examined the effect of morphine on PS-
evoked currents in CHO cells co-expressing TRPM3 and the m opioid receptor. PS evoked large cur-
rents that were reversibly inhibited by co-application of morphine (inhibition 89 ± 4%, n = 9). Exami-
nation of the current-voltage relationships before and during PS application and in the presence of
morphine (Figure 1g) showed that the response to PS was greatly inhibited by morphine at all vol-
tages studied.
Morphine is a non-selective opioid receptor agonist and DRG neurons express all three naloxone-
sensitive opioid receptor subtypes (m, d and k). We examined the effects of sub-type selective opioid
receptor agonists on PS-evoked [Ca2+]i responses of DRG neurons, to determine which receptor sub-
type is important for morphine-induced inhibition of TRPM3. Treatment with the selective k opioid
receptor agonist U50488 (20 nM), did not inhibit PS-induced responses and instead produced a
modest, but significant increase (U50488: R = 72 ± 3%; control: R = 57 ± 3%, p<0.05, Figure 2a).
The d opioid receptor agonist SB205607 (20 nM) was without effect (SB205607: R = 52 ± 3%;
p>0.05, Figure 2a), whereas the m opioid receptor agonist DAMGO (20 nM) significantly inhibited
PS-evoked [Ca2+]i-responses to an extent similar to that previously observed with morphine
(DAMGO: R = 18 ± 2%, p<0.001, Figure 2a,b). These findings indicate that morphine predominantly
inhibits TRPM3 by activating m opioid receptors and suggest a high degree of co-expression of m
opioid receptors and TRPM3. These results are in keeping with earlier observations of m (but not d)
opioid receptor expression in heat nociceptors (Scherrer et al., 2009).
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Figure 1. Morphine inhibits TRPM3 channels expressed on sensory neurons. (a) Traces of DRG [Ca2+]i responses evoked by two sequential PS
challenges (20 mM) followed by high K+ (50 mM KCl). (b) Effect of treatment with 10 mM morphine for 2 min before and during the second PS challenge.
F(340/380) indicates fura-2 emission ratio. The lower panels in (a) and (b) are pseudocolour images illustrating the change in F340/380 ratio in response to
PS and KCl. The bar indicates the colours corresponding to various F340/380 values. (c) Box and whisker plots and data points showing the amplitudes
Figure 1 continued on next page
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We next examined whether GPCR inhibition of TRPM3 was specific to opioid receptors or could
be extended to other Gi/o-coupled receptors expressed on sensory neurons. The metabotropic Gi/o-
coupled receptors for GABA, GABAB1 and GABAB2, are expressed by a high percentage (60–90%)
of peripheral sensory neurons (Charles et al., 2001; Cuny et al., 2012; Engle et al., 2012) and
Figure 1 continued
for responses to the second PS challenge in (a) and (b), ***p<0.001; Mann-Whitney U test (control, n = 174; morphine, n = 209). (d) Effect of treatment
with morphine (10 mM, n = 323), morphine (10 mM) and naloxone (1 mM, n = 110) and morphine (10 mM) following an incubation with pertussis toxin (200
ng/ml for 2.5 h-18h, n = 253) on [Ca2+]i responses evoked by the second PS (20 mM) challenge using the protocol in (a and b). Control group, n = 188.
(e) Traces displaying neuronal [Ca2+]i responses to two PS (5 mM) challenges in the absence and presence of naloxone (1 mM), followed by a 50 mM PS
challenge and high K+ (50 mM KCl). ***p<0.001, compared to control. ††† p<0.001, compared to morphine (10 mM), Kruskal-Wallis. (f) Whole cell
recording illustrating that morphine reversibly inhibits PS-evoked outward membrane currents in DRG neurons (+40 mV). (g) Inhibitory effect of
morphine on whole cell outward current in a CHO cell co-expressing TRPM3 and m-opioid receptor (+60 mV). (h) Current-voltage relationships for
another TRPM3/m-opioid receptor expressing CHO cell measured at times corresponding to time points 1–5 in panel g.
DOI: 10.7554/eLife.26138.003
Figure 2. Activation of m-opioid receptors inhibits TRPM3. (a) Effect of the selective m opioid receptor agonist DAMGO, d opioid receptor agonist
SB205607 and k opioid receptor agonist U50488 (each at 20 nM) on [Ca2+]i-responses evoked by PS (20 mM, second application, see Figure 1 for
protocol). *p<0.05, ***p<0.001; Kruskal-Wallis (control, n = 152; DAMGO, n = 184; SB205607, n = 200; U50488, n = 140). (b) Traces displaying the effect
of DAMGO (20 nM) on neuronal [Ca2+]i responses to stimulation with PS (20 mM). F(340/380) indicates fura-2 emission ratio. (c) Pseudocolour images
illustrating the change in F340/380 ratio in response to PS and KCl with the colours corresponding to various F340/380 values indicated by the bar.
DOI: 10.7554/eLife.26138.004
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recently, activation of GABAB1 was shown to modulate activity of TRPV1 channels (Hanack et al.,
2015). Treatment of DRG neurons with the selective GABAB agonist baclofen (100 mM), significantly
reduced the amplitude of the second PS response to R = 12 ± 2% compared to R = 58 ± 6% in con-
trol experiments (p<0.001, Figure 3a,b) and abolished (R < 5%) the PS-evoked [Ca2+]i responses in
67% (n = 130/194) of neurons.
The Gi/o-coupled neuropeptide tyrosine (NPY) receptors Y1 and Y2, are each expressed on 15–
20% of sensory neurons (Zhang et al., 1994, Zhang et al., 1997; Brumovsky et al., 2005; Ji et al.,
1994; Taylor et al., 2014). The Y1 receptor is predominantly expressed in small diameter neurons
whereas the Y2 receptor is largely expressed in medium and large diameter neurons. We examined
whether activation of NPY receptors by the agonist peptide YY (PYY) was able to modulate neuronal
TRPM3 [Ca2+]i-responses. Similarly to the effects of morphine and baclofen, application of 100 nM
PYY reduced the PS-evoked [Ca2+]i responses, and in 57% (n = 123/217) of neurons abolished the
evoked increase in [Ca2+]i (R < 5%). The relative amplitude of the second PS-evoked [Ca
2+]i
responses was reduced from 66 ± 3% in control experiments to 11 ± 1% in the presence of PYY
(p<0.001). Like opioid receptors, Y2 receptors have been reported to possess constitutive activity
(Chen et al., 2000) and we therefore examined whether tonic Y2 receptor activity modulates
TRPM3. In experiments where we challenged neurons with two consecutive applications of a low
concentration of PS (5 mM), treatment with the selective Y2 receptor antagonist BIIE 0246 (10mM)
significantly (p<0.05, Fisher’s) increased the number of responding neurons from 1.1% (n = 5/450) to
4.2% (19/450; Figure 3e). In contrast, the number of PS responders fell from 3.4% (n = 15/440) to
1.8% (n = 8/440) in control experiments with two applications of 5 mM PS. These findings indicate
that constitutive activity of Y2 receptors can exert a tonic inhibition of TRPM3.
To examine whether opioids, baclofen and PYY target distinct populations of TRPM3-expressing
neurons, neurons were sequentially exposed to morphine (10 mM), baclofen (100 mM) and PYY (100
nM) and challenged with PS (20 mM) in the presence and absence of these drugs (Figure 3f–h). A
large proportion of PS-sensitive neurons (43%, n = 91/210) were inhibited (response amplitude <15%
of first PS response amplitude) by all three agonists. A population of neurons was inhibited by mor-
phine and baclofen but not PYY (7%, n = 14/210) and a slightly larger percentage of neurons was
inhibited by morphine and PYY but not baclofen (13%, n = 27/210). Moreover, 10% (n = 21/210) of
neurons were inhibited by baclofen and PYY but not morphine. Small populations of neurons were
inhibited by just one agonist (morphine, 7%, n = 15/210; baclofen, 4%, n = 9/210; PYY, 4%, n = 9/
210) and a subpopulation of neurons were not inhibited by any of the agonists (15%, n = 31/210).
These findings, which are illustrated schematically in the Venn diagram (Figure 3i), indicate that mor-
phine, baclofen and PYY target overlapping populations of TRPM3-expressing neurons.
Additional experiments demonstrated that not all Gi/o-coupled receptors are able to effectively
modulate TRPM3 activity. L-AP4 (5 mM) activation of group III metabotropic glutamate receptors
(mGLUR4/6/7/8), which are expressed by DRG neurons (Carlton and Hargett, 2007; Govea et al.,
2012), had no significant effect on PS-evoked [Ca2+]I responses (R = 69 ± 3%, n = 100) compared to
control (R = 61 ± 7%, n = 20; p>0.05, Mann-Whitney U test). Cannabinoid CB1 receptors are
expressed by a subset of DRG neurons (Agarwal et al., 2007; Veress et al., 2013). The CB1 recep-
tor agonist WIN 55212–2 (1 mM) slightly but significantly reduced the amplitude of PS evoked [Ca2+]i
responses (R = 51 ± 3%; Figure 4a) compared to control (R = 62 ± 2%; p<0.001, Mann-Whitney U
test). This finding suggested that application of WIN 55212–2 inhibited PS-evoked responses in
some but not in all DRG neurons. This was confirmed when DRG neurons were challenged with 3
applications of 20 mM PS with 1 mM WIN 552212–2 present before and during the second applica-
tion and 1 mM WIN 55212–2 plus 0.5 mM AM251 (a CB1 receptor antagonist) present during the
third PS application (Figure 4b). This experimental protocol allowed for detection of neurons whose
PS evoked responses were inhibited by WIN 55212–2, and were restored when a CB1 antagonist
(AM251) was co-applied with WIN 55212–2. In many DRG neurons, WIN 55212–2 had no obvious
inhibitory effect (Figure 4b, top), but a small percentage of neurons (5%, n = 8/156) showed an
AM251-reversible WIN 552212–2 inhibition of the PS response (Figure 4b, bottom). In view of the
minor effect of CB1 receptor activation on DRG TRPM3 PS responses, we repeated the experiments
in TRPM3 CHO cells transiently transfected with the CB1 receptor. As not all cells expressed CB1
after transfection, we compared the population responses to two consecutive PS applications. PS
responses to the two PS applications were relatively stable in control cells not transfected with CB1,
whereas WIN 552212–2 inhibited the PS responses in a sub-population of CB1 transfected cells.
Quallo et al. eLife 2017;6:e26138. DOI: 10.7554/eLife.26138 6 of 22
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Figure 3. Activation of other Gi-coupled receptors also inhibit TRPM3. (a, b) Effect of (RS)-Baclofen (100 mM) on
the relative [Ca2+]i-response amplitude evoked by PS (20 mM). (c, d) Effect of PYY (100 nM) on the relative [Ca
2+]i-
response amplitude evoked by PS (20 mM). Plots illustrate the response amplitudes evoked by the second PS
challenge (% of first PS amplitude) in control experiments and experiments where neurons were perfused with (b)
Figure 3 continued on next page
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Furthermore, the second PS response of CB1 transfected cells was augmented by AM251
(Figure 4c,d). These results suggest that CB1 receptors can regulate TRPM3 but that there is either
little co-expression of TRPM3 and CB1 in DRG neurons or ineffective coupling.
We next investigated whether morphine generally affected TRP channels in DRG neurons by
examining its effect on TRPV1 responses to capsaicin. As capsaicin responses readily desensitize, we
performed the experiments in the presence of cyclosporin (1 mM) which reduces TRPV1 desensitiza-
tion (Docherty et al., 1996). DRG neurons were stimulated two or three times with 30 nM capsaicin
with morphine present before and during the second capsaicin application (Figure 5a). Morphine
had no significant inhibitory effect using this protocol (Figure 5b) in contrast to the marked inhibi-
tion of PS responses seen in the same experiments (Figure 5c).
Inhibition of TRPM3 is independent of cAMP and does not rely on Gai
proteins
Activation of Gai subunits leads to inhibition of adenylate cyclase, the enzyme responsible for pro-
ducing cAMP (cyclic 3’, 5’-adenosine monophosphate). Activation of protein kinase A (PKA) by
cAMP and the resulting regulation of ion channel functions by PKA are well characterised. In order
to examine whether opioid mediated inhibition of TRPM3 is driven by reduced levels of cAMP, we
investigated whether morphine could still exert its inhibitory effects in the presence of a membrane
permeable cAMP analogue, 8-bromo cAMP. 8-bromo cAMP was unable to compensate for the mor-
phine-induced inhibition of PS responses. In experiments where 8-bromo cAMP (1 mM) was co-
administered with morphine (10 mM) the response amplitude evoked by the second PS challenge
was 11 ± 2% (Figure 6a,b) which was similar to the amplitude in the presence of morphine alone (13
± 2%, p>0.05, Kruskal-Wallis).
In addition to initiating second messenger signalling pathways, Ga subunits can have direct
actions on ion channels. To test the involvement of Gai subunits in opioid-mediated inhibition of
TRPM3 we examined the effect of the selective Gai-inhibitor NF023 (Freissmuth et al., 1996) on
morphine-induced inhibition of PS responses. Although NF023 has been reported to inhibit Gai-
meditated signalling when applied extracellularly to cells (Sarwar et al., 2015), this charged mole-
cule probably has limited membrane permeability. We therefore examined electrophysiologically
whether intracellularly applied NF023 would modify the effect of morphine on PS evoked currents in
TRPM3/m opioid receptor expressing CHO cells (Figure 6c). Inclusion of a high concentration (100
mM) of NF023 in the patch pipette had no marked effect on the inhibitory actions of morphine
(Figure 6d,e). These findings indicate a Gai- and cAMP-independent mechanism for opioid-induced
inhibition of TRPM3.
Beta-gamma subunits of Gi proteins mediate inhibition of TRPM3
Activation of GPCRs also leads to the release of Gbg subunits which are effector molecules them-
selves and can bind directly to ion channels to modulate their function (Smrcka, 2008). We therefore
examined the effect of morphine and baclofen on PS evoked responses in the presence of a Gbg
inhibitor, gallein. Morphine induced inhibition of PS evoked {Ca2+]i-responses was dramatically
supressed by gallein (20 mM, Figure 7a,b). The response amplitude evoked by the second PS chal-
lenge was 109 ± 5% in the presence of both morphine and gallein compared to just 10 ± 1% in the
Figure 3 continued
(RS)-Baclofen (control, n = 138; Baclofen, n = 194) and (d) PYY (control, n = 289; PYY, n = 217). ***p<0.001; Mann-
Whitney U test (e) Traces displaying [Ca2+]i responses to two sequential 5 mM PS challenges, followed by a 50 mM
PS challenge and depolarisation with high K+ (50 mM KCl). Cells were exposed to 10 mM BIIE 0246 for 2 min
before and during the second PS challenge. (f–h) Traces displaying DRG [Ca2+]i responses to sequential 20 mM PS
challenges (indicated by black bars) in the presence and absence of morphine (10 mM), baclofen (100 mM) and PYY
(100 nM), followed by depolarisation with high K+ (50 mM KCl). A group of cells were inhibited by some GPCR
agonists but not others. F(340/380) indicates fura-2 emission ratio. (i) Venn diagram illustrating the pattern of
inhibition of PS responses by morphine, baclofen and PYY, n = 210 PS and KCl responsive cells. Responses in 31
cells were not inhibited by any of the GPCR agonists (second response amplitude >15% of first PS response
amplitude).
DOI: 10.7554/eLife.26138.005
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Figure 4. CB1 activation can inhibit TRPM3 channels. (a) Effect of CB1 receptor agonist WIN 55212–2 (1 mM) on DRG [Ca2+]i-responses evoked by PS
(20 mM, second application). ***p<0.001; Mann-Whitney U test (control, n = 213; WIN 55212–2, n = 218). (b) Traces showing DRG [Ca2+]i responses to
three PS (20 mM) challenges in the absence and presence of WIN 55212–2 (1 mM) and WIN 55212–2 (1 mM) plus AM251 (0.5 mM) followed by high K+ (50
mM KCl). Many PS responses were unaffected by WIN 55212–2 (upper panel) and some showed an inhibition that was reversed by co-application of the
antagonist AM251 with WIN 55212–2 (bottom panel). (c) Traces displaying [Ca2+]i responses to sequential 20 mM PS challenges (indicated by black bars)
in CHO cells co-expressing TRPM3 and CB1 receptors in the absence (top) and presence (middle) of 1 mM WIN 552212–2 during the second PS
challenge. Middle traces show cells where WIN 552212–2 inhibited the PS responses. Bottom: [Ca2+]i responses to sequential applications of 5 mM PS
with 0.5 mM present during the second PS application. (d) Plots showing the change in [Ca2+]i response amplitudes (second – first response). Note the
increased number of negative values (inhibition) and the increased number of positive values (potentiation) in the presence of the agonist WIN 552212–
2 and antagonist AM251, respectively.
DOI: 10.7554/eLife.26138.006
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Figure 5. Morphine does not inhibit capsaicin evoked [Ca2+]i-responses. Cyclosporin (1mM) included in all
solutions to reduce TRPV1 desensitization. (a) Traces showing DRG [Ca2+]i responses to three capsaicin (1 mM)
challenges (indicated by black bars) followed by high K+ (50 mM KCl). Morphine (10 mM was present) before and
during the second capsaicin challenge. Lower panels are pseudocolour images illustrating the change in F340/380
Figure 5 continued on next page
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presence of morphine alone. In additional experiments with three PS challenges, a group of neurons
were identified which showed reduced responses (<30% of first response) to PS when morphine (10
mM) was present but regained sensitivity (>50% of first response) when gallein (20 mM) was also pres-
ent (Figure 7c,d).
Figure 5 continued
ratio in response to capsaicin and KCl. (b) Plots showing the change in [Ca2+]i response amplitudes (second – first
response) under control conditions (left, Caps/Caps) and when morphine was applied (middle, Caps/Mor + Caps).
(c) 10 mM morphine reduced [Ca2+]i responses evoked by 20 mM PS in same experiment. Amplitudes of responses
evoked by first PS application (left) and second application of PS in presence of morphine (right). ***p<0.001
DOI: 10.7554/eLife.26138.007
Figure 6. Opioid-mediated inhibition of TRPM3 is independent of cAMP and Gai subunits. (a) Traces showing the effect of 8-bromo cAMP (1 mM) on
morphine (10 mM) induced inhibition of [Ca2+]i–responses evoked by PS (20 mM) in DRG neurons. F(340/380) indicates fura-2 emission ratio. (b) Box and
whisker and scatter plots displaying the average response amplitudes from experiments such as a., control, n = 96; morphine, n = 95; morphine +8
bromo cAMP, n = 118) ***p<0.001, compared to control. (c) Whole cell recordings illustrating morphine inhibition of PS-evoked outward membrane
currents in CHO cells co-expressing TRPM3 and the m opioid receptor (+60 mV) in the absence (left) and presence (right) of 100 mM NF023 in the
pipette solution. (d) Box and whisker and scatter plots showing the percentage inhibition of 50 mM PS-evoked currents in the absence and presence of
NF023. No significant difference noted (p=0.1).
DOI: 10.7554/eLife.26138.008
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Figure 7. bg subunits mediate Gi/o inhibition of TRPM3. (a, b) Effect of the Gbg inhibitor gallein (20 mM) on morphine (10 mM) induced inhibition of PS-
evoked [Ca2+]i-responses. (a) Plots show the relative response amplitudes evoked by a second PS challenge (20 mM) in control conditions, in the
presence of morphine and gallein, control n = 52; morphine n = 314; morphine + gallein n = 153. (b) Representative traces demonstrating that gallein
reverses morphine inhibition of PS (20 mM). Cells were perfused with 10 mM morphine 2 min before and during the second and third PS challenge, and
perfused with 20 mM gallein 7 min before and during the third PS challenge. The results shown are for morphine sensitive cells (PS response amplitude
in presence of morphine < 30% of the first response amplitude). ***p<0.001 compared to control, †††p<0.001 compared to morphine, Kruskal Wallis.
Figure 7 continued on next page
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We next examined whether gallein also prevents baclofen-induced inhibition of PS-evoked
[Ca2+]i-responses. When both gallein (10 mM) and baclofen (100 mM) were present during the second
PS application, the maximum response amplitude was significantly higher than when baclofen was
present alone (gallein and baclofen: 38 ± 4%, baclofen: 12 ± 2%, p<0.001, (Figure 7e,f). Similarly,
the inhibitory effect of PYY (100 nM) on PS-evoked [Ca2+]i-responses was attenuated in the presence
of gallein (20 mM); the maximum response amplitude in the presence of both gallein and PYY was
significantly higher than the maximum response amplitude in the presence of PYY alone (gallein and
PYY: 36 ± 3%, PYY: 21 ± 2%, p<0.001). Intriguingly, the scatter plots suggest that the inhibitory
effect of gallein on baclofen and PYY mediated inhibition only occurred in a subset of neurons,
unlike the strong effect noted for morphine inhibition in almost all cells. Nevertheless, these results
indicate that TRPM3 activity can be regulated by a bg-dependent mechanism after activation of opi-
oid, GABAB and NPY receptors.
To determine whether TRPM3 can be inhibited directly by Gbg subunits in the absence of GPCR
stimulation and Gai activation, we examined electrophysiologically the effect of intracellularly dialys-
ing TRPM3 expressing HEK293 cells with Gbg subunits (50 nM). Application of PS (50 mM) for 10 s
every minute evoked large outward currents in TRPM3 HEK293 cells, without any detectable desen-
sitization (Figure 8a,b). In contrast, intracellular dialysis with bg-subunits (50 nM) produced a signifi-
cant and progressive inhibition of the PS-evoked current amplitude (Figure 8a,b). To confirm the
inhibitory effects of Gbg subunits on TRPM3 we applied Gbg subunits to the intracellular face of
inside-out membrane patches from TRPM3 HEK293 cells stimulated with another, specific TRPM3
agonist, CIM0216. Macroscopic CIM-0216-evoked currents in these patches were greatly inhibited
by 50 nM Gbg subunits (Fig, 8 c, e) but not by administration of Gbg subunits that had been heat
denatured by boiling (Figure 8d,e). These results are consistent with direct inhibition of TRPM3 by
Gbg subunits.
Gi/o coupled GPCRs modulate TRPM3 mediated nociceptive responses
We determined the effects of TRPM3 modulation in vivo by examining the nociceptive responses
evoked by TRPM3 agonists in wild-type mice. Previous studies in TRPM3 knockout mice have shown
that the behavioural responses to intraplantar injection of PS and CIM0216, are dependent on
TRPM3 (35). The behavioural responses to either agonist alone were often mild. We therefore
administered a combination of 5 nmole PS and 0.5 nmole CIM-0216 as these compounds have been
shown to act synergistically in vitro (Held et al., 2015). Intraplantar administration of the combined
agonists evoked robust paw licking/flinching behaviour that was measured over a 2 min period. Prior
intraplantar administration of morphine (130nmole) essentially abolished the behavioural response
evoked by PS/CIM0216 (Figure 9a), and intraplantar injections of either baclofen (240nmole) or PYY
(235pmole) also significantly reduced the response (Figure 9b). Behavioural responses could be
inhibited by morphine acting on, for example, voltage gated potassium channels in the periphery.
We therefore examined the effects of intraplantar morphine on the paw licking/flinching responses
evoked by intraplantar injection of capsaicin. Morphine had no inhibitory effect on capsaicin-elicited
behaviours (Figure 9e) in marked contrast to its effect on PS/CIM0216 responses.
Naloxone and BIIE0246 act as inverse agonists at m opioid and NPY Y2 receptors (Elbrønd-
Bek et al., 2015; Wang et al., 2001) and consequently inhibit constitutive GPCR activity as well as
inhibiting agonist evoked responses. As these ligands augmented TRPM3 activity in DRG neurons in
vitro, we examined if they would increase the nociceptive effects of TRPM3 agonists. For these stud-
ies we used intraplantar injection of PS alone, which evoked relatively mild behavioural responses.
Figure 7 continued
(c) Scatter and line plot showing the relationship between maximum response amplitudes (D Fura-2 ratio) for the first, second and third PS responses in
control experiments without gallein and (d) in experiments with gallein (20 mM) present during the third PS application. (e,f) Plots displaying the relative
response amplitudes evoked by the second (20 mM) PS challenge for control experiments and experiments where neurons were perfused with (e) 100
mM baclofen or 10 mM gallein and 100 mM baclofen (control, n = 88 baclofen, n = 236; baclofen and gallein, n = 102). ***p<0.001 compared to control,
†††p<0.001 compared to baclofen, Kruskal Wallis. (f) Effect of 100 nM PYY or 10 mM gallein and 100 nM PYY on the relative amplitude of PS evoked
[Ca2+]i-responses (control, n = 65; PYY, n = 288; PYY and gallein, n = 183). ***p<0.001 compared to control, ††p=0.01 compared to PYY. Kruskal-Wallis.
F(340/380) indicates fura-2 emission ratio.
DOI: 10.7554/eLife.26138.009
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Prior intraperitoneal administration of either 2.5 mg/kg naloxone (Figure 9d) or 3 mg/kg BIIE0246
(Figure 9e) resulted in significantly increased nociceptive responses to PS.
Discussion
TRPM3 is expressed in DRG neurons where it plays a role in the transduction of thermal (heat) stimuli
in normal conditions and notably in the development of heat hypersensitivity in inflammatory condi-
tions (Vriens et al., 2011). Studies of TRPM3 have been facilitated by the discovery of PS and the
synthetic compound CIM0216 as TRPM3 agonists (Wagner et al., 2008; Held et al., 2015) that can
be used to probe the functions and characteristics of TRPM3, and we have utilised these compounds
to investigate the regulation of TRPM3 channels by GPCR ligands. Like other TRP channels, TRPM3
activity is regulated by intracellular PI(4,5)P2 and other phosphoinositides (Badheka et al., 2015;
Figure 8. Effect of bg subunits on PS-evoked currents. (a) Outward currents (+40 mV) evoked by 10 s PS (50 mM) applications every minute in TRPM3-
expressing HEK293 cells. Cells dialysed intracellularly with bg subunits (50 nM, red trace) showed a progressive decline in the evoked current amplitude
compared to control cells. (b) Column graph displaying normalised current (% of maximum current) for PS-evoked outward currents in TRPM3-
expressing HEK293 cells. Columns represent mean ± SEM; **p<0.01, ***p<0.001, unpaired t-test (control, n = 3–5 cells; bg , n = 3–5 cells). (c) bg
subunits (50 nM) applied to the intracellular face of an inside out membrane patch from TRPM3-expressing HEK293 cell inhibit 10 mM CIM0216 evoked
outward current (+60 mV). (d) Heat inactivated (100˚C, 10 min) bg subunits (50 nM) do not inhibit CIM0216 evoked currents. (e) Plots of percentage
inhibition of CIM0216 evoked currents in inside out membrane patches for bg subunits (n = 5) and boiled bg subunits (n = 6).** p=0.002
DOI: 10.7554/eLife.26138.010
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Figure 9. Nociceptive responses to TRPM3 agonists are modulated by Gi GPCR ligands. (a,b) Inhibitory effects of prior (5 min) intraplantar
administrations of (a) 130 nmole morphine (n = 6 for each group) and (b) 240 nmole baclofen (n = 6) or 235 pmole PYY (n = 8) on the duration of licking/
flinching evoked by intraplantar injection of 5 nmole PS plus 0.5 nmole CIM-0216 (n = 10 for PS + CIM0216). (c,d) Effects of prior (30 min) intraperitoneal
administration of either (c) 2.5 mg/kg naloxone (n = 9 for PS, n = 8 for PS + naloxone) or (d) 3 mg/kg BIIE 0246 (n = 11 for PS, n = 8 for PS + BIIE 0246)
Figure 9 continued on next page
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To´th et al., 2015) but otherwise little is known about the mechanisms that regulate the activity of
this channel. Other sensory neuron TRP channels, notably TRPV1 and TRPA1, are regulated down-
stream of GPCR signalling by mechanisms that involve either Gq activation, PI(4,5)P2 hydrolysis and
protein kinase C or Gs activation leading to protein kinase A mediated phosphorylation. These and
other phosphorylation pathways are important regulatory mechanisms for TRP channels particularly
in inflammatory conditions (see Veldhuis et al., 2015 for review). Activation of the Gi coupled m opi-
oid receptor is a potent analgesic mechanism in sensory systems and opioid agonists such as mor-
phine can inhibit TRPV1 activity by reducing phosphorylation levels; however, this is evident only
when TRPV1 is sensitized via the cAMP-PKA pathway (Endres-Becker et al., 2007; Vetter et al.,
2006, 2008). This latter observation is consistent with our observation that morphine has little or no
inhibitory effect on capsaicin evoked Ca2+ responses when desensitization is blocked by cyclosporin.
Our results demonstrate for the first time that agonists acting at several Gi coupled GPCRs (m opi-
oid, GABA-B and NPY receptors) exert an inhibitory effect on TRPM3 activation in DRG neurons.
This inhibitory effect was PTX-sensitive demonstrating a Gi/o protein involvement. The inhibition was
not, however, mediated by the canonical Ga subunit/adenylate cyclase pathway as the inhibitory
effect was not abrogated by either application of the Ga subunit inhibitor NF023 or by providing a
membrane permeable cAMP analogue that is well known to activate PKA. Instead, our results indi-
cate that the TRPM3 inhibition is mediated by Gbg subunits. The Gai inhibitor NF023, which inhibits
Gai subunit interactions with effector molecules, was without effect when dialysed into cells at 100
mM which is higher than its IC50 value (~300–400 nM). However, Ga subunits bind to effector mole-
cules with picomolar to nanomolar affinities and the effectiveness of NF023 will depend on its rela-
tive binding affinity for Gai compared to that of the effector molecules. We therefore cannot be
certain that NF023 effectively inhibits Gai signalling even at the concentration used. In contrast, we
have clear evidence for a role for Gbg subunits.
The inhibitory effects of morphine on TRPM3 were reversed by gallein, which is generally consid-
ered to be a specific inhibitor of Gbg signalling (Lin and Smrcka, 2011), although we cannot exclude
a non-Gbg ‘off target’ effect. Critically, we found that PS evoked currents were inhibited by direct
application of purified Gbg subunits to either whole cells or excised inside-out membrane patches,
without concomitant activation of Gai or G-protein-coupled receptors. The effect of the Gbg subu-
nits was lost after heat inactivation indicating that proteins in the sample were responsible for the
inhibitory activity. Our findings are therefore consistent with activation of a m opioid receptor and an
action of Gbg subunits to inhibit TRPM3. A direct interaction between the released Gbg subunits
and TRPM3 is likely as found for some other ion channels (Elbrønd-Bek et al., 2015; Wang et al.,
2001; Veldhuis et al., 2015). Gbg subunits can, however, activate other molecules such as phospho-
lipase C (Rebecchi and Pentyala, 2000), and such an action would hydrolyse PI(4,5)P2 and reduce
TRPM3 activity (Badheka et al., 2015; To´th et al., 2015). Inhibition of TRPM3 activity could there-
fore be due to a Gbg/PLCmediated loss of PI(4,5)P2. PI(4,5)P2 levels are not maintained in isolated
membrane patches and decline rapidly especially in the absence of Mg-ATP, which is required for
phosphoinositide kinase mediated generation of PI(4,5)P2 (Zakharian et al., 2011). This loss of PI
(4,5)P2, accounts for the greatly reduced TRPM3 channel activity previously reported in excised
membrane patches (Badheka et al., 2015; To´th et al., 2015). In our excised inside-out patch experi-
ments, recordings were made minutes after excision into Mg-ATP free solution, which will deplete PI
(4,5)P2, and no further run down of channel activity was noted during the recordings. The finding
that Gbg subunits exerted a robust inhibitory effect on TRPM3 currents in membrane patches in
these conditions suggests that the Gbg inhibition does not involve PLC mediated hydrolysis of PI
(4,5)P2. Such a conclusion is further supported by the observations in DRG Ca
2+ imaging experi-
ments where, in contrast to TRPM3, TRPV1 responses were not affected by morphine. As the activi-
ties of both channels are modulated by PI(4,5)P2 hydrolysis (Badheka et al., 2015; Cao et al., 2013),
Figure 9 continued
on licking/flinching behaviour evoked by intraplantar administration of 5nmole PS. *p<0.05, **p<0.01, ***p<0.001; ANOVA followed by Tukey’s HSD
test. (e) No effect of intraplantar morphine (130 nmole) on nociceptive responses evoked by intraplantar administration of capsaicin (33 nmole). Vehicle,
0.9% NaCl.
DOI: 10.7554/eLife.26138.011
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the differential, strong inhibition of TRPM3 cannot be explained by PLC activation and a reduction in
PI(4,5)P2.
Direct effects of G protein subunits on ion channel functions have been well studied for P/Q- and
N-type voltage gated calcium channels (Dolphin, 2003) and Kir channels (Dascal, 1997;
Yamada et al., 1998). In contrast, there is relatively little knowledge of direct G protein subunit -
TRP channel interactions. TRPM1 channels are inhibited by activation of Go–linked GPCRs and the
available evidence is consistent with regulation by interactions direct between TRPM1 and both Gao
and Gbg subunits (Shen et al., 2012; Xu et al., 2016; Devi et al., 2013; Koike et al., 2010). In other
studies, TRPM8 was shown to be inhibited by an interaction with Gaq (Zhang et al., 2012; Li and
Zhang, 2013) while TRPA1 activation following stimulation of MrgprA3 receptors in DRG neurons
was inhibited by gallein and phosducin, consistent with a Gbg mediated mechanism (Wilson et al.,
2011). TRP channel regulation by direct G protein subunit interactions is therefore emerging as an
important and novel mechanistic concept.
DRG neurons showed differential sensitivity to activation of different GPCRs. The TRPM3
responses in many neurons were inhibited by more than one GPCR agonist consistent with expres-
sion of multiple GPCRs in these neurons. Presumably the inhibition pattern reflects the distribution
and expression levels of the different GPCRs. However, not all Gi/o GPCR agonists inhibited TRPM3.
The group III mGluR agonist, L-AP4, and agonists at d- and k-opioid receptors did not significantly
inhibit TRPM3 responses although there is good evidence for their expression in DRG neurons
(Scherrer et al., 2009; Carlton and Hargett, 2007; Govea et al., 2012; Honsek et al., 2015;
Wang et al., 2010). In part this could be explained by lack of TRPM3-GPCR co-expression in individ-
ual DRG neurons. For example, d-opioid receptors are expressed by about 15% of, mainly larger
diameter, DRG neurons (Scherrer et al., 2009; Bardoni et al., 2014) although there is evidence for
some co-expression of m- and d-opioid receptors (Devi et al., 2013), There is also likely to be an
overlap in expression of Gi/o –coupled metabotropic glutamate GPCRs (Carlton and Hargett, 2007;
Govea et al., 2012) with the small-medium diameter DRG neurons that express TRPM3
(Vriens et al., 2011). A significant inhibition of TRPM3 responses would therefore be expected in
some DRG neurons, as seen for CB1 receptor activation (Agarwal et al., 2007; Veress et al., 2013).
The effect of CB1 receptor activation in DRG neurons was restricted to a small number of neurons,
although our experiments with heterologously expressed TRPM3 and CB1 indicated that CB1 recep-
tor activity can regulate TRPM3. It is possible that specific macromolecular assemblies are required
for the efficient interaction between types of GPCRs and TRPM3 and that d- and k-opioid and
mGluR receptors do not contribute to these complexes, and that CB1 receptors are variably coupled
in DRG neurons. The pronounced inhibition of TRPM3 by m-opioid receptor activation is interesting
as this receptor sub-type is expressed in mice in heat sensitive DRG neurons (see Scherrer et al.,
2009; Honsek et al., 2015) and may be functionally relevant for opioid control of heat sensation.
An interesting additional finding was that while both baclofen and PYY robustly inhibited TRPM3
responses in a substantial percentage of DRG neurons, this inhibitory effect was only partially
reversed by gallein. In contrast, gallein strongly reversed the inhibitory effect of morphine on
TRPM3. This finding raises the possibility that Gi/o-coupled GPCRs can regulate TRPM3 via several
signalling pathways.
In addition to demonstrating GPCR agonist induced inhibition of TRPM3, our in vitro studies have
revealed that inverse agonists that act at m-opioid and NPY receptors (naloxone and BIIE0246) can
potentiate TRPM3 mediated responses. These findings are consistent with the concept that constitu-
tive activity of m-opioid and NPY receptors provides a level of tonic inhibition of TRPM3. A potentiat-
ing effect of these ligands was also noted in vivo, where they potentiated the behavioural effects of
local intraplantar injection of PS. This result could reflect an inhibition of constitutive GPCR activity,
as suggested by the in vitro findings, or inhibition of endogenous GPCR agonists produced in the
tissues. Intraplantar administration of morphine, baclofen or PYY inhibited the strong nociceptive
behavioural responses evoked by combined local application of PS and CIM0216. Such a peripheral
anti-nociceptive action could be due to an action that inhibits action potential transmission, perhaps
by activation of voltage gated potassium channels. However, morphine did not inhibit TRPV1-medi-
ated, capsaicin-evoked pain responses so a general inhibitory action of morphine on the transmission
of nociceptive signals can be ruled out. The inhibition of TRPM3-mediated nociceptive responses by
the GPCR agonists can therefore be correlated to TRPM3 inhibition. Our results demonstrate that
GPCR modulation of TRPM3 occurs in vivo and that the effects are localized to the regions of
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sensory nerve terminals rather than systemic effects operating at the level of the spinal cord or
higher centres in the nociception pathway.
Our results demonstrate that TRPM3 in sensory neurons is subject to Gi/o GPCR regulation via a
Gbg subunit action. Activation of m-opioid and GABA-B receptors are important analgesic mecha-
nisms that operate both peripherally and centrally, including actions on the central terminals of sen-
sory nerves in the spinal dorsal horn. Given the co-expression of TRPM3 and these GPCRs in
nociceptive sensory neurons and the emerging role of TRPM3 in nociception, our findings highlight
the importance of determining the role of TRPM3 in pathophysiological pain conditions.
Materials and methods
Cell culture
DRG neurons were prepared from adult male or female C57Bl/6J mice using methods described
previously48. Isolated neurons were plated on poly-d-lysine coated coverslips and maintained at
37˚C in an atmosphere of 95% air-5% CO2 in MEM AQ (Sigma, Poole, UK) supplemented with 10%
fetal bovine serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin, and 50 ng/ml NGF (Promega,
Southampton, UK) for up to 24 hr before experimentation. HEK293 cells (RRID:CVCL_U427, Thermo-
Fisher Scientific) stably expressing TRPM3a2 plasmid (pcDNA3.1) DNA (provided by Dr Stephan
Philipp; University of Saarland, Homburg, Germany) were grown in DMEM AQ supplemented with
penicillin (100 U/ml), streptomycin (100 mg/ml), FBS (10%) and G418 (0.5 mg/ml). CHO cells (RRID:
CVCL_U424, ThermoFisher Scientific) stably expressing TRPM3a2 were grown in MEM AQ media
with the same supplements noted for HEK293 cell growth. For some experiments, TRPM3 HEK293
or CHO cells were transiently transfected with plasmids encoding mouse m opioid receptor-IRES-
GFP (pCMV6, NM_001039652) or GFP tagged-rat CB1 receptor (pEGFP-N1, NM_012784.4), using
Lipofectamine 2000 according to the supplier’s protocol. All cells used were mycoplasma free.
Imaging changes in intracellular calcium levels
DRG neurons were loaded with 2.5 mM Fura-2 AM (Molecular Probes) in the presence of 1 mM pro-
benecid for ~1 hr. Dye loading and all experiments were performed in a physiological saline solution
containing (in mM) 140 NaCl, 5 KCl, 10 glucose, 10 HEPES, 2 CaCl2, and 1 MgCl2, buffered to pH
7.4 (NaOH). Drug solutions were applied to cells by local microsuperfusion of solution through a fine
tube placed very close to the cells being studied. The temperature of the superfused solution (24–
25˚C) was regulated by a temperature controller (Marlow Industries) attached to a Peltier device
with the temperature measured at the orifice of the inflow tube. Images of a group of cells were cap-
tured every 2 s at 340 and 380 nm excitation wavelengths with emission measured at 520 nm with a
microscope based imaging system (PTI, New Jersey, USA). Analyses of emission intensity ratios at
340 nm/380 nm excitation (R, in individual cells) were performed with the ImageMaster suite of
software.
Electrophysiology
DRG neurons and TRPM3 expressing HEK293 or CHO cell lines were studied under voltage-clamp
conditions using an Axopatch 200B amplifier and pClamp 10.0 software (RRID:SCR_011323, Molecu-
lar Devices). DRG neuron recordings were performed at +40 or+60 mV using borosilicate electrodes
(3–6 MW) filled with (in mM): 140 CsCl, 10 EGTA, 1 CaCl2, 2MgATP, 2 Na2ATP, buffered to pH 7.4
(CsOH). DRG neurons were studied in the extracellular solution used for [Ca2+]i-measurements (see
above). HEK293 and CHO cells were studied under Ca2+-free conditions (same solution as above,
but with CaCl2 substituted by 1 mM EGTA). Excised inside-out membrane patch recordings were
made using TRPM3 expressing HEK293 cells. The solution bathing the intracellular membrane face
of excised membrane patches contained either (mM) 140 CsCl, 10 EGTA, 10 HEPES or 70 CsCl,
70NMDG-Cl, 10 EGTA, 10 HEPES pH7.3. For some experiments current-voltage relationships were
obtained from voltage ramps (300 ms duration) from  100 mV to voltages up to +200 mV. The
NMDG containing intracellular solution was used for voltage ramp studies to reduce the amplitude
of the outward current.
bg subunits from bovine brain (Millipore Ltd., Watford, UK) were dissolved in intracellular solution
at a final concentration of 50 nM. For some experiment the bg subunits were inactivated by heating
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to 100˚C for 10 min. bg subunits (plus CIM0216) were applied by pressure ejection from a blunt
pipette positioned close to the excised membrane patch.
Behavioural assessment of pain responses
All behavioural experiments were approved by the King’s College London Animal Welfare and Ethi-
cal Review Board and conducted under the UK Home Office Project Licence PPL 70/7510. PS, or a
combination of PS/CIM0216 (25 ml) and morphine, baclofen and PYY (10 ml) were injected subcutane-
ously into the plantar surface (intraplantar, i.pl.) of one of the hind paws using a 50 ml Luer-syringe
(Hamilton Co.) fitted with a 26-gauge x 3/8 inch needle. Morphine, baclofen and PYY were injected
5 min before PS/CIM0216. Naloxone (2.5 mg/kg) and BIIE 0246 3 mg/kg were injected intraperitone-
ally 30 min prior to intraplantar injection of PS. Mice were habituated to the experimental Perspex
chambers before the experiment and placed in the chambers immediately after injection of TRPM3
agonists. The duration of pain-related behaviours (licking and biting or flinching and shaking of the
injected paw) was recorded using a digital stop-watch. Total pain response times over the first 2 min
were used for analysis as the pain behaviours were largely restricted to this period. Groups of 6–11
animals were used for each agent. Pregnenolone sulphate (PS,): a 200 mM solution in PBS was pre-
pared from a 60 mM DMSO stock solution. 25 ml was injected i.pl. into the left hind paw. CIM0216:
a 20 mM solution was prepared from a 5 mM DMSO stock solution. A combined PS/CIM solution
was prepared by combining 1 ml 400 mM PS with 1 ml 40 mM CIM and 25 ml was injected i.pl. into
the left hind paw. Naloxone HCl was administered at a dose of 2.5 mg/kg i.p. 30 min prior to PS.
Morphine, 100 mg in 10 ml was injected i.pl. 5 min prior to CIM/PREGS. Baclofen, 60 mg in 20 ml was
injected i.pl. 5 min prior to CIM/PS. PYY, 1 mg in 10 ml was injected i.pl. 5 min prior to CIM/PS. BIIE
0246 was made up in saline from a 10 mM DMSO stock and dosed at 3 mg/kg i.p. 60 min prior to
PS.
Materials
All compounds were from Sigma-Aldrich, Poole, UK unless otherwise stated. Stock solutions of preg-
nenolone sulphate, CIM0216 (Tocris Bioscience; Bristol, UK), WIN 55212–2 (Tocris Bioscience; Bristol,
UK), AM251 (Tocris Bioscience; Bristol, UK), Gallein (Santa Cruz Biotechnology; Heidelberg, Ger-
many) and BIIE 0246 (Tocris Bioscience; Bristol, UK) were made in DMSO (Calbiochem; Darmstadt,
Germany). Stock solutions of morphine and naloxone were made in H2O and DAMGO (Tocris Biosci-
ence; Bristol, UK), SB205607 (Tocris Bioscience; Bristol, UK), U50488 (Tocris Bioscience; Bristol, UK)
and PYY (ABGent; San Diego, CA), were made in physiological extracellular solution. A stock solu-
tion of 8-bromo cAMP was made in H2O titrated with NaOH. Stock solutions of L-AP4 (Tocris Biosci-
ence; Bristol, UK) and (RS)-Baclofen (Tocris Bioscience; Bristol, UK) were made in molar equivalent
solutions of NaOH. Stock solutions were aliquoted and stored at  20˚C. Stock solutions were diluted
in physiological extracellular solution for their use in experiments. PTX (lyophilised powder) was
reconstituted in H2O and was stored at 4˚C. PTX was added to cells at a concentration of 200 ng/ml.
Statistical analysis
Data are presented as box and whisker plots showing the mean (square symbol), median (horizontal
line), interquartile range (box) and 5% and 95% percentile points (whiskers). For the microfluorimetry
and electrophysiology experiments, ‘n’ values represent the number of PS responding neurons or
cells studied except where indicated otherwise in the text. For behavioural experiments, ‘n’ values
represent the number of animals in each group. No statistical methods were used to predetermine
sample sizes, however our sample sizes are similar to, or greater than, those generally employed in
other studies in the field. Normality of data was tested using the Shapiro-Wilk Test. Differences in
normally distributed data means between two groups were analysed using an independent samples
t-test. Differences in normally distributed data means between three groups or more were analysed
using a one-way ANOVA, followed by a Tukey’s HSD post-hoc test. Differences in non-normally dis-
tributed data means between two groups were analysed using a Mann-Whitney U test. Differences
in non-normally distributed data means between three groups or more were analysed using a Krus-
kal-Wallis test. All statistical analyses were made using IBM SPSS statistics, version 22 (RRID:SCR_
002865).
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